NCT04186494View on ClinicalTrials.gov

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

July 31, 2022

Conditions
Sleep Apnea, Obstructive
Interventions
DRUG

Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml

GLP-1 analogue treatment in combination with advice on diet and physical exercise

DEVICE

Continuous positive airway pressure treatment

Gold standard treatment for obstructive sleep apnea

COMBINATION_PRODUCT

Liraglutide and CPAP

Combination of both treatments

Trial Locations (1)

Unknown

St Vincent's University Hospital, Dublin

All Listed Sponsors
collaborator

University College Dublin

OTHER

collaborator

Health Research Board, Ireland

OTHER

lead

St Vincent's University Hospital, Ireland

OTHER

NCT04186494 - Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter